Clinical Trials Directory

Trials / Unknown

UnknownNCT03103191

Diagnostic Value of KL-6 in ILD

Diagnostic Value of KL-6 in Interstitial Lung Diseases

Status
Unknown
Phase
Study type
Observational
Enrollment
250 (estimated)
Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

KL-6 may be a useful biomarker in patients with interstitial lung disease, but there is limited information in non-Asian populations. Therefore, it is necessary to carry out studies in other populations to confirm the diagnostic values of the biomarker and its prognostic implication. Hypothesis KL-6 may be a useful biomarker in the management of interstitial lung diseases. But it is necessary to know more about its utility in the European population. Study Objectives: * To determine the concentration of KL-6 in serum of patients with pulmonary fibrosis at the time of diagnosis compared to patients without pulmonary fibrosis * Diagnostic yield of KL-6 in patients with pulmonary fibrosis. * Correlation of KL-6 values with functional and radiological parameters of disease severity at diagnosis. * Correlation of serum KL-6 values with the evolution of the disease.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTKL-6 levelsMeasure of KL-6 in serum

Timeline

Start date
2016-06-01
Primary completion
2022-12-01
Completion
2023-12-01
First posted
2017-04-06
Last updated
2020-08-18

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT03103191. Inclusion in this directory is not an endorsement.